Health Canada has published the answer. The EU is still working on a consistent one.
At the end of March 2026, Health Canada published the final version of its guidance on how to interpret significant change for licensed Class III and IV medical devices. The previous version dated from 2011, so it was overdue. Whether you sell into Canada or not, it is worth paying attention to, because the way Health Canada approaches this question says something useful about how regulatory transparency can work when a regulator puts its mind to it.
This post looks at what Health Canada has done well, and then asks a fair question about EU MDR and the CE marking system: when a manufacturer needs to decide whether a change to their device requires notified body involvement, how consistent is the answer they will get, and where does that answer actually come from?
Table of Contents
What Health Canada has published
The new significant change guidance is a single, publicly available document, written by the regulator, applicable to all licensed Class III and IV medical devices, covering every major category of change a manufacturer is likely to encounter. Design changes, manufacturing process changes, software updates, sterilisation changes, materials changes, labelling changes, changes to compatible devices across risk classes: all of it is addressed in one place, with worked examples giving real-world scenarios and clear determinations of whether each is significant or not.
It also introduces some well-considered concepts. The four-corner testing principle, which holds that a change falling within the performance envelope of existing licensed device variants is generally non-significant, is clearly explained and illustrated, with carve-outs for non-linear behaviour. The guidance addresses machine learning-enabled devices and predetermined change control plans, which is a more forward-looking position than some regulators have managed. It also deals explicitly with the cumulative effect of multiple simultaneous changes, not just individual ones in isolation, which is where real-world change management tends to get complicated.
Crucially, it is free, public, and written by the people whose decision you ultimately need. A manufacturer anywhere in the world can read it before submitting anything to anyone. A small company without a large regulatory department can use it to do a defensible first-pass assessment of their own change. Isn’t that what we want – manufacturers to understand how to be compliant?
How the CE & EU MDR systems handle the same question
The EU Medical Device Regulation has two distinct frameworks for significant or substantial change, and understanding which applies to a given device matters a great deal.
For legacy devices, those still operating under MDD or AIMDD certificates during the transitional period, MDCG 2020-3 Rev.1 (published May 2023) provides detailed guidance on what constitutes a significant change in design or intended purpose under Article 120(3). It is well-constructed, uses flowcharts, includes worked examples, and was developed by the Medical Device Coordination Group. For this population of devices, the EU has produced something comparable in spirit to what Health Canada has now done, even if the underlying regulatory context differs.
For devices already fully certified under the MDR, the relevant framework is Annex IX of the MDR, specifically sections 2.4 and 4.10. These require manufacturers to inform their notified body of substantial changes to the quality management system or device range covered, and require notified body approval before implementing changes that could affect safety, performance, or conditions of use. That obligation is clear in law. What is considerably less clear is the detail of what it means in practice, because there is no harmonised MDCG guidance document for this pathway. There is, in other words, no EU equivalent of the document Health Canada just published for manufacturers on fully MDR-certified devices.
Where the guidance actually comes from
In the absence of a harmonised MDCG document for Annex IX substantial changes, notified bodies have filled the gap themselves, with predictably varied results.
GMED publishes a comprehensive 25-page guide covering substantial changes under Annex IX in detail, with worked examples across design, materials, sterilisation, software, QMS, labelling, and manufacturing. It explicitly distinguishes Article 120 significant changes from Annex IX substantial changes, which is a distinction that matters enormously because the consequences of each determination are entirely different. A manufacturer holding a GMED certificate has access to substantive published guidance they can work through before they pick up the phone.
SGS publishes a structured change notification form with an annex listing categories of substantial change. It is a working form rather than an explanatory guide, but it contains genuine category-level content and is publicly available. TUV SÜD publishes an equivalent notification form. Both are useful as far as they go, though neither attempts the explanatory depth of the GMED guide.
BSI does not publish an equivalent public guide for Annex IX substantial changes. BSI operates a proprietary internal change notification form and has acknowledged in its own published communications that guidance gaps exist in certain areas. Manufacturers seeking to understand BSI’s criteria in advance are largely dependent on their contractual relationship and direct engagement with their scheme manager.
Even the terminology is inconsistent
Adding to the difficulty, the MDR uses the term substantial change in the context of Annex IX and significant change in the context of Article 120. These are different concepts with different consequences, but they are frequently conflated, including in some notified body documentation. The Johner Institute, a respected independent source on MDR implementation, has noted that the terms are used inconsistently across the industry and recommends that manufacturers make an explicit agreement with their notified body as to which framework applies to each change being assessed. That a specialist institute feels the need to issue that advice tells you something about where things currently stand.
Health Canada has none of this ambiguity. Significant change means one thing, applies to one population of devices, triggers one type of application, and is described in one publicly available document from the regulator.
The European Commission has noticed
This is not merely an industry observation. In December 2025, the European Commission published a draft Implementing Regulation aimed at harmonising notified body practices under the MDR and IVDR. The Commission’s own explanatory materials acknowledged divergent interpretations and practices across notified bodies in relation to conformity assessment activities. A public consultation on the draft closed in January 2026.
That is progress. It is also confirmation that the variability is real and significant enough to warrant legislative intervention. Given that NBOG BPG 2014-3 already existed, surely its not a great leap to update in line with MDR/IVDR?
What this means in practice
For manufacturers selling into Canada, the new Health Canada guidance is useful and timely. It is thorough, free, publicly available, and written by the regulator whose decision you ultimately need. If you are reviewing your change management SOP or updating your QMS to reflect current Canadian requirements, the new guidance is your starting point, and the worked examples are directly usable for documenting your own change determinations.
For manufacturers selling into the EU, or advising companies that do, the picture is more layered. The framework is legally sound and the Annex IX obligation is clear. For legacy devices under MDCG 2020-3, the guidance is comparable to what Health Canada has now produced. For fully MDR-certified devices, the practical experience of a substantial change notification depends on who your notified body is, what they have published, and what your contract specifies. That is not a criticism of any individual notified body. It is a description of a system that has operated without harmonised guidance for this pathway, and which the Commission is now working to address.
In the meantime, the most practical advice is familiar: know which framework applies to each device in your portfolio, document your determinations carefully, and engage your notified body early when a change sits anywhere near the boundary. Regulatory uncertainty is not a reason to delay the conversation. It is, if anything, a reason to start it sooner.
A final thought
There is something worth noting about the process behind what Health Canada has done. The guidance went through public consultation in 2024, took on board stakeholder feedback, and arrived as a final document that is demonstrably more comprehensive and better illustrated than the version it replaces. It reflects a regulator that took the task seriously.
The EU system, at its best, aspires to the same standard. MDCG 2020-3 Rev.1 is evidence that it can get there. The question is whether the same clarity will arrive for the Annex IX substantial change pathway, and how long manufacturers will be navigating a notified-body-dependent patchwork in the meantime. We can only hope that the Commission’s current harmonisation work delivers something with the depth and accessibility of what Health Canada has just published.